Eli Lilly’s retatrutide beats Ozempic in Phase 3 head‑to‑head diabetes trial
Eli Lilly reported that its investigational triple‑hormone drug retatrutide produced a larger drop in A1C and more than double the weight loss of Novo Nordisk’s Ozempic in the 80‑week TRANSCEND‑T2D‑2 Phase 3 trial. The study enrolled about 1,300 adults with type 2 diabetes and compared retatrutide 9 mg and 12 mg doses against Ozempic 2 mg. Lilly’s executive said the data could shift the treatment paradigm if the drug receives approval.
Why it matters
Lilly says the results could shift the treatment paradigm for type 2 diabetes and obesity, opening a new premium product line. Analysts note the drug could generate up to $15 billion in sales by 2032, pressuring competitors.
Key facts
- 1Retatrutide lowered A1C by an average of 2.2% versus 1.8% for Ozempic 2 mg at 80 weeks. prnewswire.com
- 2Participants on retatrutide lost 44.3 lb (19.5%) at the 9 mg dose and 47.4 lb (20.9%) at the 12 mg dose, compared with 20.9 lb (9.4%) on Ozempic. prnewswire.com
- 3The trial enrolled 1,298 adults with type 2 diabetes. stocktitan.net
- 4Retatrutide was given at 9 mg and 12 mg once weekly. investor.lilly.com
- 5Treatment discontinuation due to adverse events was 4.8% (9 mg) and 7.9% (12 mg) versus 2.7% for Ozempic. prnewswire.com
- 6The primary and all key secondary endpoints were met at 80 weeks. prnewswire.com
Summary written by AlphAI AI Desk from 20 of 28 sources. Not investment advice. Figures are as stated by the linked sources.